The Phase II VISION study of tepotinib has revealed durable anti-tumour clinical activity across different lines of treatment in advanced non-small cell lung cancer (NSCLC), announced Merck. Tepotinib has shown effective in NSCLC patients harbouring MET exon 14 skipping mutations.
Alterations of the MET signaling pathway, including MET exon 14 skipping mutations and MET amplifications, occur in 3-5% of NSCLC cases which correlate with aggressive tumour behavior and poor clinical prognosis.
“Patients with this NSCLC molecular subtype lack treatment options that have the potential to significantly improve clinical outcomes,” said Paul K. Paik, M.D., primary study investigator and Clinical Director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center.
Tepotinib is an investigational, selective1 oral MET kinase inhibitor that is designed to inhibit the oncogenic signaling caused by MET (gene) alterations or MET protein overexpression. The mutations were detected in patients by liquid biopsy (LBx) or tissue biopsy (TBx).
The new data from Phase II VISION study showed tepotinib induced objective responses in 50% of patients identified by lLBx and 45.1% of patients identified by TBx. Median duration of response was 12.4 months for LBx-identified patients and 15.7 months for TBx-identified patients.
“Tepotinib has been designed to potentially improve outcomes in aggressive tumours that have a poor prognosis and harbour these specific alterations,” said Luciano Rossetti, Global Head of Research & Development for the Biopharma business of Merck.
“Tepotinib is an important part of our strategic focus on precision medicine, and both the proportion of patients responding and the duration of anti-tumour clinical activity demonstrate the potential of this investigational therapy.” he stated.
The updated results of the study was presented by Merck at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, US.